Sponsored Content
LIGHT AI (CBOE: ALGO)
A BRAND NEW Opportunity in Health and AI
“AI-Powered Health Insights
- Right From Your Smartphone.”
With Light AI's patented tool, it only takes 45 seconds to get health insights
– without even leaving your home…
Disclosure: Owners, members, directors and employees of Katusa Research have/may have stock or option position in any of the companies mentioned: LIGHT AI. Katusa Research receives compensation for this publication and has a business relationship with any company whose stock(s) is/are mentioned in this article.
This content was reviewed and approved by LIGHT AI
Key Specs of this Opportunity:
You wake up one morning and instantly feel the scratching in the back of your throat.
It feels like someone hooked a razorblade to your tonsils.
Right away, you wonder…
Should I just stay in bed or haul myself to the doctor to have it checked out?
That would involve getting dressed, dealing with traffic, waiting in a room full of other sick people, and getting examined.
But those days could soon be over…
“Dr. AI” is coming – Pending regulatory validation, Light AI aims to assist in identifying potential Strep A cases.
Light AI – a small AI developer is now public on the Canadian stock exchange (CBOE: ALGO) – developed AI-powered health software that you can use on your own phone.[i]
Designed to be used at home, Light AI aims to complement traditional healthcare by providing additional insights.
When you get strep throat, your doctor still does what they did in the 1950s.
They stick a wooden paddle in your mouth, shine a flashlight down your throat, and then they are required to take a swab and send it to a lab to be cultured.
Imagine screening for strep throat with your smartphone. No doctors. No wooden paddles.
Early testing suggests Light AI’s AI model may provide promising accuracy in screening for potential Strep A cases. Further validation and regulatory approvals are required before commercial deployment.
You can see the development curve from the LightAI website below to a 96.5% accuracy level…
Source: LightAI investor presentation Jan 2025. Results based on early-stage studies; further validation is required before regulatory approval.
Strep A affects 600 million people every year.
And that only counts people that go to the doctor and get diagnosed…
The actual number might be a lot higher.
Most Strep A infections start out as a harmless sore throat.
But that harmless scratch in your throat can quickly turn into a deadly disease if left untreated…
In fact, scarlet fever usually starts out as just a sore throat.
But if this illness is not treated quickly, it can lead to multiple organ failure – and death.
The World Health Organization (WHO) lists Strep A as…
In fact, Strep A kills about 500,000 people worldwide every year.[3]
That’s half a million lives lost every year!
And incredibly, a lot of those deaths – if not all of them – are preventable.
Strep A bacteria are usually very responsive to common forms of antibiotics that are readily available in most countries.[4]
But if that antibiotic doesn’t reach the patient in time, it can turn catastrophic…
The first step in the line of treatment is the correct diagnosis. [5]
Antibiotics for Strep A bacteria can save lives – if diagnosed quickly and correctly.
And that’s where Light AI comes in.
The AI application has learned through analyzing more than 300,000 images of throats infected by Strep A bacteria.
Based on this massive database, studies have shown that it can rule out whether an illness is caused by one of the 120 strains of Strep A…
Or whether it’s a harmless virus that will resolve on its own.
And it does so within seconds…
Right now, you’d have to wait at least 24 hours to get your lab results back.
Here’s how Light AI’s (CBOE: ALGO) app works…
When you wake up with a sore throat in the morning, all you have to do is…
- Grab your phone
- Take a picture of your throat
- Wait 10 seconds
And done.
Light AI analyzes the image of your mouth against more than 300,000 other images it has learned from.
This is the future of medicine.
And it’s one of the first AI medical applications that doesn’t need a middleman to analyze the results. Light AI’s technology is designed to offer AI-assisted health insights, pending regulatory validation.
The stock began listing on the Canadian stock exchange as “ALGO” on January 8, 2025.[6]
AI is already changing the medical industry…
Doctors and hospitals are using AI to not only help them save time and money – but to help save lives.
And in many cases, AI is better than the doctors themselves…
AI Doctors vs. Human Doctors – The Race for Accuracy?
And those are just some of the most common illnesses…
When it comes to rare diseases, AI can be better than a human doctor. That’s because AI has access to a much bigger data base than a person could ever search through.[8]
Some studies even showed up to 99% accuracy in certain illnesses.[9]
That’s nearly flawless.
No wonder doctors across many disciplines have already integrated AI into their work, including…
- Cancer
- Heart disease
- Alzheimer’s
- Skin conditions
- Glaucoma
- Lung diseases
And it doesn’t stop at hospitals and clinics…
More than 80% of pharmaceutical workers are using AI to speed up new drug development[10]
In 2020, a British startup developed a drug to treat obsessive-compulsive disorder that was entirely created by AI.[11]
Normally, a drug takes five years to get to the trial stage.
AI did it in just 12 months.
Even patients can directly benefit from using AI…
Did you ever try to Google your symptoms to figure out what’s going on?
Most private internet searches for medical conditions inevitably lead a patient to find the most unlikely, scariest diagnosis available.
Which is exactly why doctors discourage patients from going that route.
And then ChatGPT came around…
Suddenly, even seasoned doctors had to admit that their patients are showing up with incredibly accurate assessments of their own conditions.
A neurologist at Yale University, who was long a critic of searching the internet for medical information, had to admit that his patients’ assessments weren’t that far off from his own.[12]
But now, we’ve entered a new stage of development in the AI medical field…
And it will unlock not only the potential to save numerous lives but…
This is early stage AI development
Light AI wants to take AI-powered healthcare to a whole new level.
Instead of searching for your symptoms in AI chatbots or internet browsers and having to choose from the multiple possibilities…
Light AI’s application does a lot of that work for you – and early results indicate way more accurately than you ever could. It analyzes throat images to assist in health screening, providing additional insights to users.
Because Light AI doesn’t just rely on your words.
It bases its assessment on what it can see for itself, compared to at least 300,000 other patients that came before you.[13]
It’s the closest thing to a personal at-home doctor you can get.
Now, Light AI isn’t available to private patients yet.
But that’s just a matter of time…
In fact, Light AI has three upcoming paths to the commercial market.
Three paths to profits for Light AI (CBOE: ALGO)
The company has three ways to make its AI software available to people who need it.
All three are in progress and should be ready – or close to ready – for mass market reach by the end of 2025.
Here’s how LightAI will reach the masses…
Path to Profits 1: Direct-to-consumer product in a market that will 15X over the next ten years
The biggest market opportunity for LightAI is to release the app – with all of its functions – as a direct-to-consumer wellness app.
This will open up the largest market for the company…
AI in healthcare is already worth $22 billion.[14]
But that’s nothing…
Over the next 10 years, it’s expected to grow by 15X to more than $370 billion.[15]
The official launch of the app on Apple and Android devices is planned for the second half of this year.
The next path is more difficult, but worth the wait…
Path to Profits 2: FDA authorization that allows for insurance coverage in the United States
In order to be used by doctors and clinics, LightAI’s app needs to be approved by the FDA as an SaMD (Software as a Medical Device).[16]
This would not only allow doctors to avoid the lengthy – and expensive – process of going through an external lab to get a diagnosis…
But it would allow patients to have both their assessment and treatment covered by their insurance providers.
This is huge…
Healthcare is one of the biggest expenses in any household or federal budget.
In Canada, for example, healthcare expenses in 2024 reached more than $370 billion – or $9,000 per citizen.[17]
In the United States, annual healthcare spending is at an average of almost $15,000 per person.[18]
But in order to be covered by insurance, a drug or medical device needs to be approved by the FDA.
LightAI is already in discussions with FDA officials about a path to approval.
The required study, which will prove effectiveness and safety, is scheduled for the second half of this year. Approval is tentatively expected by the second half of next year.
As anyone familiar with investing in healthcare companies knows…
Any of these milestones on the way to FDA approval can be great catalysts for a company’s share price.
But that’s not all…
Path to Profits 3: Help save lives where Strep A is the deadliest
Strep A bacteria affect 600 million people all over the world.
But they’re most dangerous in areas without easy access to a healthcare provider – especially in remote areas of Africa.
Studies show that only half of the African population has access to the healthcare services they need.[19]
And Light AI’s easy phone application could be a lifesaver for people with little access to a doctor, let alone a lab.
The company has lined up Tech Care For All (TC4A) as a distribution partner to make its app available to 120,000 healthcare practitioners in more than 20 countries.
The initial focus is on rollout in Kenya and Uganda, as well as initial clinical studies in Nigeria and South America.
In Kenya, Strep A has a mortality rate of 12% among children.[20]
After these two countries, LightAI will roll out in TC4A’s 16 other distribution countries.
Even one of these paths to profits could bring Light AI a windfall in revenue over the next few years…
Now, you might wonder…
If AI in the medical field is so prevalent already…
And Strep A is such a common and relevant problem…
Aren’t there competitors who are ready to swoop in and take Light AI’s first mover advantage?
Here’s where LightAI has built an iron-clad competitive moat…
Competitive Moat #1: The company has already secured 4 patents on its technology in the United States and Europe
Three of these patents specifically cover the image processing of Strep A bacteria with AI technology.
And the fourth – and most important one – is a broad patent on the use of image data to discover infections.
In addition to those crucial patents in the biggest healthcare markets in the world, Light AI has one more patent granted in Australia and four more pending in other countries, including Canada, Europe and Israel.
These patents will make sure that competitors will have to pay LightAI to use their proprietary technology if they want to have access to their consumer base.
Competitive Moat #2: 13 years of AI development on more than 300,000 images
Light AI has been developing this revolutionary AI technology for the past 13 years.
This doesn’t just include years of experience among its leadership rank and employees…
It also includes years of training of its AI software.
See, just like human doctors…
AI doesn’t just become a “doctor” overnight.
Artificial intelligence is a game changing technology not because it’s a brand-new invention.
In fact, AI has been around in some form for decades…
But it has taken off in recent years because of rapid developments in processing power of computer chips.
In order to work well, AI needs to “train” on existing data to improve over time.
The more data it trains on, and the longer, the better it gets.
Light AI has years of training and tons of data ahead of any of its future competitors.
In fact, the Strep A software has already been trained on more than 300,000 images.
And with each of these images, the accuracy of detection has improved.
Today, pre-FDA studies have shown that it can rule out bacterial infection with an incredible 97%.
Take a look at its accuracy progression over the last eight years…
Anyone hoping to beat Light AI at its own game will need to invest the time and money to send its AI through this “training” period.
Otherwise they will always have an inferior product – and Light AI will win in the market.
Meanwhile, Light AI will continue to improve its AI capabilities and add more diseases to its software.
And they’re doing that with…
A top-notch team with decades of healthcare experience, including medical giants like Johnson & Johnson, Bristol Myers-Squibb and the CDC
The founder and CEO alone, Peter Whitehead, is the inventor of VELScope, an oral cancer examination tool that is used by over 10,000 dental practices in over 23 countries.
Based on his experience with VELScope, he clearly knows how to take a medical device global…
Peter has 24 years of experience working in the healthcare field.
And he is joined by veterans from the medical industry as well as experts in the development of artificial intelligence.
But isn’t AI in bubble territory by now?
Many AI stocks have seen their share prices skyrocket over the last few years.
Nvidia alone went up 2,308% in just the past five years.[21]
And this meteoric rise has many analysts worried that AI stocks will pull back this year.
But that’s only the case for companies that create generative AI – the kind that’s used in ChatGPT and other AI search engines.
The type of AI that has barely gotten off the ground is specialized AI – the kind that turns a particular industry upside down.
Like AI in healthcare, which is currently a comparatively small $20 billion industry…
But is projected to grow to an incredible $370 billion in under ten years – 15X more than it is now.
As an AI company though, LightAI already benefits from the hype that’s still ongoing for any company using AI.
Make no mistake…
Artificial intelligence is the biggest mega trend of this century.
It will not only change our daily lives…
But it will unleash an unimaginable amount of money for those that invest in its development.
We’re only at the beginning of this technological revolution
And if you want to get a piece of the fortune that AI will create over the next few years, Light AI is one of the best places to start right now…
Here’s why you should consider Light AI (CBOE: ALGO) today:
- Light AI has a successful and developed product that’s ready to launch in just months…
- Light AI just went public on the Canadian stock exchange only, which means it’s still under the radar of most investors, especially in the US…
- Light AI solves an important and urgent problem for hundreds of millions of people around the world…
- Light AI has three separate paths to profits, which offers security of revenue if one of them is delayed or doesn’t work as planned…
- And Light AI benefits from the ongoing hype around AI in the news media…
Light AI (CBOE: ALGO) is publicly traded
Investors should carefully evaluate all available information before making decisions.
You’ve seen what its product can do…
You’ve seen what the potential behind this market is…
Now it’s on you to decide whether you’ll take a shot at this opportunity…
Or watch it from the sidelines.
If you want to review any of the information you’ve just read, you can download the company’s latest investor presentation right here.
- https://www.gettyimages.com/detail/photo/doctor-examining-patients-throat-in-doctors-office-royalty-free-image/107429850?phrase=doctor%20examining%20throat&searchscope=image%2Cfilm&adppopup=true ↑
- https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/streptococcus-pyrogenesStreptococcus pyogenes (group A streptococci, or GAS) is a major cause of death and disability globally, particularly in low- and middle-income countries. ↑
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5776658 ↑
- https://www.cdc.gov/group-a-strep/php/ltcf-toolkit/antibiotic-regimens.htmlGAS is universally susceptible to beta-lactam antibiotics, including penicillin and cephalosporins. ↑
- Image source pill bottle: https://www.gettyimages.com/detail/photo/close-up-of-a-male-hand-holding-a-pill-bottle-royalty-free-image/1635084121?phrase=antibiotics&searchscope=image%2Cfilm&adppopup=true ↑
- https://finance.yahoo.com/news/light-ai-announces-closing-offering-164500775.html ↑
- Data:
Pneumonia
Breast Cancer
Prostate cancer
Human doctors = 73%
Human doctors = 74%
Human doctors = 67%
AI doctors = 96%
AI doctors = 91%
AI doctors = 84%
Pneumonia: https://bmcmededuc.biomedcentral.com/articles/10.1186/s12909-023-04698-z
deep learning algorithms are used to detect pneumonia from chest radiography with sensitivity and specificity of 96% and 64% compared to radiologists 50% and 73%, respectively
Breast Cancer: https://bmcmededuc.biomedcentral.com/articles/10.1186/s12909-023-04698-z
AI was better at detecting early breast cancer (91%) than radiologists 74%
Prostate Cancer: https://nypost.com/2024/07/20/health/ai-detects-cancer-with-17-more-accuracy-than-doctors-ucla-study
A new study from UCLA found that an AI tool identified prostate cancer with 84% accuracy — compared to 67% accuracy for cases detected by physicians, according to a press release from the university. ↑ - https://hms.harvard.edu/news/how-ai-can-help-diagnose-rare-diseases ↑
- https://beckman.illinois.edu/about/news/article/2024/03/04/new-ai-model-draws-treasure-maps-to-diagnose-disease#:~:text=Researchers%20at%20the%20Beckman%20Institute,explain%20the%20results%20to%20patients.The new model performed comparably to its counterparts in all three categories, with accuracy rates of 77.8% for mammograms, 99.1% for retinal OCT images, and 83% for chest x-rays compared to the existing 77.8%, 99.1%, and 83.33.% ↑
- https://www.mgma.com/articles/artificial-intelligence-in-diagnosing-medical-conditions-and-impact-on-healthcareA survey found that 80% of pharmaceutical and life sciences professionals are currently using AI for drug discovery.11 This collaboration leverages the strengths of AI and healthcare professionals. ↑
- https://www.bbc.com/news/technology-51315462?utm_source=chatgpt.comA drug molecule "invented" by artificial intelligence (AI) will be used in human trials in a world first for machine learning in medicine.It was created by British start-up Exscientia and Japanese pharmaceutical firm Sumitomo Dainippon Pharma.The drug will be used to treat patients who have obsessive-compulsive disorder (OCD).Typically, drug development takes about five years to get to trial, but the AI drug took just 12 months. ↑
- https://www.scientificamerican.com/article/ai-chatbots-can-diagnose-medical-conditions-at-home-how-good-are-they/ChatGPT was only released last November, but Tolchin says at least two patients have already told him they used it to self-diagnose symptoms or to look up side effects of medication. The answers were reasonable, he says. ↑
- https://www.gettyimages.com/detail/photo/senior-man-using-smart-phone-at-table-royalty-free-image/1343473312?phrase=Ai%20healthcare&searchscope=image%2Cfilm&adppopup=true ↑
- https://www.globenewswire.com/news-release/2024/08/30/2938549/0/en/Artificial-Intelligence-in-Healthcare-Market-to-Hit-USD-370-14-Billion-by-2032-Fuelled-by-AI-Integration-in-Diagnostics-and-Treatment-SNS-Insider.html ↑
- https://www.globenewswire.com/news-release/2024/08/30/2938549/0/en/Artificial-Intelligence-in-Healthcare-Market-to-Hit-USD-370-14-Billion-by-2032-Fuelled-by-AI-Integration-in-Diagnostics-and-Treatment-SNS-Insider.html ↑
- https://medcitynews.com/2020/08/how-to-get-nationwide-reimbursement-for-novel-medical-technology/What is the road to nationwide local Medicare coverage of a novel technology? It has to start with a medical milestone of course – FDA approval of an innovative treatment method. ↑
- https://www.cihi.ca/en/national-health-expenditure-trends-2024-snapshotTotal health expenditures in Canada are projected to reach $372 billion, or $9,054 per Canadian. ↑
- https://www.usatoday.com/story/money/2024/12/28/why-american-health-care-costs-more/77264782007/The United States spent $4.87 trillion on health care in 2023, according to an analysis by KFF. That’s $14,570 per person. ↑
- https://healthpolicy-watch.news/only-half-of-africans-have-access-to-health-care/?utm_source=chatgpt.com ↑
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4734542/?utm_source=chatgpt.comResearch conducted in rural Kenya reported an overall case-fatality rate of 12% among children with invasive GAS infections. ↑
- https://finance.yahoo.com/quote/NVDA/chart/ ↑
IMPORTANT DISCLAIMER & DISCLOSURES
Investing in stocks is HIGH RISK. You could lose all of your investment.
Katusa Research, as a publisher, is not a broker, investment advisor, or financial advisor in any jurisdiction.
Please do not rely on the information presented by Katusa Research as personal investment advice.
If you need personal investment advice, kindly reach out to a qualified and registered broker, investment advisor, or financial advisor.
The communications from Katusa Research should not form the basis of your investment decisions. Examples we provide regarding share price increases related to specific companies are based on randomly selected time periods and should not be taken as an indicator or predictor of future stock prices for those companies.
LightAI Inc. is a paid sponsor of this report.
The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom.
Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Katusa Research nor any employee of Katusa Research is not registered with the United States Securities and Exchange Commission (the “SEC”): as a “broker-dealer” under the Exchange Act, as an “investment adviser” under the Investment Advisers Act of 1940, or in any other capacity. Katusa Research, its owners, directors, and employees are also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.
HIGHLY BIASED: In our role, we aim to highlight specific companies for your further investigation; however, these are not stock recommendations, nor do they constitute an offer or sale of the referenced securities. Katusa Research partner company, New Era Publishing Inc. has received cash compensation in the amount of three hundred seventy-five thousand dollars from LightAI Corp. for a four-week marketing campaign. and is thus extremely biased. It is crucial that you conduct your own research prior to investing. This includes reading the companies’ SEDAR and SEC filings, press releases, and risk disclosures. The information contained herein regarding LightAI Inc. has been derived from its SEDAR+ and SEC filings, including scientific and technical information. Information regarding the projects underlying LightAI Inc.’s interests has been derived from the publicly available disclosure of the underlying operators and owners, including where referenced herein.
Katusa Research, and its directors, employees, and members of their households may own any shares of LightAi Inc (ALGO:CBOE). However, Katusa Research is extremely biased since this is a sponsored editorial.
HIGH RISK: The securities issued by the companies we feature should be seen as high risk; if you choose to invest, despite these warnings, you may lose your entire investment. You must be aware of the risks and be willing to accept them in order to invest in financial instruments, including stocks, options, and futures.
NOT PROFESSIONAL ADVICE: By reading this, you agree to all of the following: You understand this to be an expression of opinions and NOT professional advice. You are solely responsible for the use of any content and hold Katusa Research, and all partners, members, and affiliates harmless in any event or claim. While Katusa Research strives to provide accurate and reliable information sourced from believed-to-be trustworthy sources, we cannot guarantee the accuracy or reliability of the information. The information provided reflects conditions as they are at the moment of writing and not at any future date. Katusa Research is not obligated to update, correct, or revise the information post-publication.
FORWARD-LOOKING STATEMENTS: Certain information presented may contain or be considered forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in these statements. There can be no assurance that any such statements will prove to be accurate, and readers should not place undue reliance on such information. These statements are subject to known and unknown risks including those set forth in LightAI Inc.’s most recent annual information form and other public filings available at www.sedarplus.ca and www.sec.gov. Neither Katusa Research nor LightAI Inc. undertake any obligations to update the information presented or to ensure that such information remains current and accurate, except as required under applicable law.